EQL PHARMA AB (7JK) - Total Assets
Based on the latest financial reports, EQL PHARMA AB (7JK) holds total assets worth €813.54 Million EUR (≈ $951.11 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check 7JK capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
EQL PHARMA AB - Total Assets Trend (2022–2025)
This chart illustrates how EQL PHARMA AB's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of EQL PHARMA AB to evaluate the quality of earnings relative to operating cash generation.
EQL PHARMA AB - Asset Composition Analysis
Current Asset Composition (March 2025)
EQL PHARMA AB's total assets of €813.54 Million consist of 49.5% current assets and 50.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.2% |
| Accounts Receivable | €125.68 Million | 15.5% |
| Inventory | €179.03 Million | 22.1% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €402.25 Million | 49.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2022–2025)
This chart illustrates how EQL PHARMA AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EQL PHARMA AB (7JK) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: EQL PHARMA AB's current assets represent 49.5% of total assets in 2025, a decrease from 51.9% in 2022.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2025, down from 17.3% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 46.0% in 2022.
- Asset Diversification: The largest asset category is intangible assets at 49.7% of total assets.
EQL PHARMA AB Competitors by Total Assets
Key competitors of EQL PHARMA AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
EQL PHARMA AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 1.23 | 1.24 |
| Quick Ratio | 1.03 | 0.45 | 0.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €202.36 Million | €48.60 Million | €45.79 Million |
EQL PHARMA AB - Advanced Valuation Insights
This section examines the relationship between EQL PHARMA AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.68 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | 116.4% |
| Total Assets | €808.82 Million |
| Market Capitalization | $73.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values EQL PHARMA AB's assets below their book value (0.09x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: EQL PHARMA AB's assets grew by 116.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for EQL PHARMA AB (2022–2025)
The table below shows the annual total assets of EQL PHARMA AB from 2022 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | €808.82 Million ≈ $945.60 Million |
+116.40% |
| 2024-03-31 | €373.76 Million ≈ $436.96 Million |
+30.82% |
| 2023-03-31 | €285.70 Million ≈ $334.01 Million |
+20.10% |
| 2022-03-31 | €237.89 Million ≈ $278.12 Million |
-- |
About EQL PHARMA AB
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.